Hagerty (HGTY) insider continues divestment with new 11.7k-share plan
Rhea-AI Filing Summary
Form 144 filing for Hagerty, Inc. (HGTY) discloses a notice of proposed insider sales by Robert I. Kauffman through Aldel LLC.
Proposed sale: 11,710 common shares to be executed around 06/23/2025 on the NYSE through Merrill Lynch, representing roughly 0.013% of the 90,032,391 shares outstanding. Estimated market value is $117,334.
Historical sales (last three months): The same insider has already disposed of ≈423,457 shares between 03/17/2025 and 06/20/2025 across 48 separate transactions, generating disclosed gross proceeds exceeding $4.0 million (sum of table line items). The individual transactions ranged from 1,149 to 33,765 shares per day.
The securities were originally acquired on 12/02/2021 as part of a PIPE investment related to Hagerty’s 2021 business-combination transaction. No gifts or non-cash consideration are reported.
The filer attests to the absence of undisclosed material adverse information and makes the customary Rule 10b5-1 representations.
Positive
- None.
Negative
- Continued insider selling: Approximately 423,457 shares already sold in the last three months and a new notice for 11,710 more may weigh on market sentiment.
- No offsetting positive corporate news: Filing contains no operational or financial updates to balance the perception of insider divestiture.
Insights
TL;DR: Insider plans another small sale after offloading ~423k shares; dilution negligible but sentiment mildly negative.
The filing shows continued selling by Robert I. Kauffman, a PIPE investor, who intends to sell an additional 11.7 k shares—just 0.013 % of shares outstanding—following three months of sizable divestitures amounting to ~0.47 % of total float. While the absolute stake sold is modest relative to market cap, persistent insider selling could pressure near-term sentiment, especially given aggregate proceeds above $4 m. No new corporate information is revealed and there is no effect on capital structure beyond secondary liquidity. I view the filing as low-impact to fundamentals but a slight negative signal for momentum-focused investors.
TL;DR: Routine Rule 144 disclosure; governance risk low, but sustained insider selling may raise optics concerns.
Form 144 compliance looks proper: live filing, broker identified, full Rule 10b5-1 representation, and prior sales disclosed. The volume does not breach 1 % in any 3-month window, keeping within Rule 144 safe-harbor limits. Governance risk is minimal; however, investors may question alignment as the insider continues to trim holdings post-SPAC merger. No red flags on undisclosed adverse information.
